# 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma

> **NCT00088868** · PHASE1 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 40 (estimated)

## Conditions studied

- Lymphoma
- Small Intestine Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** alvespimycin hydrochloride

## Key facts

- **NCT ID:** NCT00088868
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-06
- **Primary completion:** 2010-03
- **Final completion:** 2010-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2012-03-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00088868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00088868, "17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00088868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*